ArticleScientific reports2025
Using network toxicology and molecular docking to identify core targets and pathways underlying tacrolimus-induced tremor in organ transplant recipients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics integration identifies ribosome biogenesis-active macrophage subpopulation and its key gene GNL2 in driving liver hepatocellular carcinoma progression and mechanisms.Cancer cell international · 2026Article
- Localized Tacrolimus Delivery for Peripheral Nerve Regeneration: Molecular Mechanisms, Biomaterial Platforms, and Translational Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tacrolimus, the most commonly prescribed immunosuppressant following organ transplantation, is associated with various neurotoxic effects, notably tremor, which significantly impacts the quality of life of recipients. The precise mechanisms underlying tacrolimus-induced tremor remain unclear. To investigate this, we employed network toxicology and molecular docking methodologies to identify potential targets and pathways. The SMILES representation of tacrolimus was retrieved from the PubChem database, and toxicity predictions were performed using ProTox-3.0 and ADMETlab 3.0. Targets related to tacrolimus and tremor-associated diseases were identified from public databases. Protein-protein interaction networks and functional enrichment analyses were conducted using STRING and Cytoscape. Molecular docking studies were carried out with CB-Dock2. A total of 43 potential targets associated with tacrolimus exposure and tremor were identified, out of which five core targets were filtered through STRING and Cytoscape analyses: AKT1, GBA, SCN8A, SCN2A, and SCN4A. Functional enrichment analysis highlighted several critical pathways implicated in tacrolimus-induced tremor, including the Dopaminergic synapse, Parkinson's disease, Rap1 signaling pathway, Spinocerebellar ataxia, and Apoptosis. The results of molecular docking indicated that tacrolimus exhibits the strongest binding affinity toward SCN8A and SCN2A among the core targets. This study suggests that tacrolimus-induced tremor may be closely linked to parkinsonian tremor and provides a theoretical foundation for understanding the neurotoxic effects of tacrolimus. Given the limited research in network toxicology on the specific molecular mechanisms involved, further animal studies are warranted to elucidate these mechanisms in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.